Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredient Tafamidis / Tafamidis Meglumin

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredient Iron(Iii) Sodium D-Gluconate Complex

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Substance Fondaparinux (Atc Code According to Who: B01ax05)

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Epoetin Zeta (Recombinant Human Erythropoietin)

Open House Biologics Rebate Contracts 2023-07 - Pegvisomant

Completion of Non-exclusive Drug Discounts According to Section 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Fondaparinux (atc Code According to Who: B01ax05)

Completion of Non-exclusive Drug Discounts According to Section 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Epoetin Zeta (recombinant Human Erythropoetin)

Degree Non-Excl. am Discount Agreements According to Section 130A Paragraph 8 Sgb V Iwe So-Called Open-House Model for the Ws Ibuprofen (Atc Code According to Who: M01ae01), Film-Coated Tablets/Retard Tablets

Open House Original Discount Contracts 2023-11 - Glycopyrronium Bromide (Dosage Form: Hard Capsules with Powder for Inhalation)